Vasculitis Workup
For suspected vasculitis, immediately obtain ANCA testing (both PR3 and MPO by antigen-specific immunoassay), urinalysis with microscopy, inflammatory markers (ESR/CRP), and pursue tissue biopsy when feasible—but do not delay treatment if clinical presentation and positive ANCA strongly suggest ANCA-associated vasculitis. 1
Initial Laboratory Assessment
Essential Serological Testing
ANCA testing is the cornerstone of small vessel vasculitis diagnosis. Use high-quality antigen-specific immunoassays (ELISA for PR3-ANCA and MPO-ANCA) as the primary screening method, not immunofluorescence alone 1. This approach has 75-95% sensitivity in ANCA-associated vasculitis 2.
Core laboratory panel includes:
- ANCA testing (PR3 and MPO by antigen-specific assay) 1
- Urinalysis with microscopy - looking specifically for glomerular hematuria, red cell casts, and proteinuria 3, 4
- Inflammatory markers - ESR and CRP (though nonspecific, they are highly sensitive for large vessel vasculitis) 5
- Serum creatinine with eGFR calculation 3
- Complete blood count - assess for eosinophilia (EGPA), anemia, thrombocytopenia 6
- Hepatitis B and C serology - essential to exclude secondary vasculitis 7
Additional Serological Tests Based on Clinical Context
For small vessel vasculitis with immune complex features:
- Anti-GBM antibodies (if rapidly progressive glomerulonephritis) 4
- Anti-C1q antibodies 3
- Complement levels (C3, C4) 3
- Cryoglobulins (if purpura, arthralgias, or hepatitis C positive) 7
- Serum immunoglobulins 3
For eosinophilic granulomatosis with polyangiitis (EGPA):
- Total eosinophil count 6
- Serum vitamin B12 and tryptase (to exclude neoplastic hypereosinophilia) 6
- IgE levels (particularly if considering omalizumab for refractory asthma) 6
Tissue Biopsy Strategy
Biopsy remains the gold standard for confirming vasculitis and should be pursued whenever safely feasible 3, 1. However, the critical caveat: if clinical presentation is compatible with ANCA-associated vasculitis and PR3- or MPO-ANCA is positive, do not delay immunosuppressive therapy waiting for biopsy results, especially in rapidly deteriorating patients 4, 8.
Biopsy Site Selection by Vessel Size
For large vessel vasculitis (Giant Cell Arteritis):
- Temporal artery biopsy for suspected cranial GCA (obtain ≥1 cm length for multiple sections) 5
- Perform biopsy within 1-2 weeks of starting glucocorticoids (treatment prior to biopsy is acceptable and unlikely to affect results) 5
- Contralateral biopsy not routinely indicated unless high clinical suspicion with negative initial biopsy 5
For small-medium vessel vasculitis:
- Kidney biopsy - highest yield in renal involvement (91.5% in GPA with glomerulonephritis) 3
- Skin biopsy - readily accessible when cutaneous lesions present 6
- Nerve/muscle biopsy - for suspected mononeuritis multiplex 6
- Lung biopsy - transbronchial has low yield (12% for GPA); open or video-assisted thoracoscopic biopsy preferred if pulmonary involvement is isolated 3
- ENT biopsy - up to 68.4% positive in GPA with upper airway involvement, though often shows nonspecific inflammation 3
For Takayasu arteritis: Tissue biopsy rarely obtained due to inaccessibility; diagnosis relies on imaging 9
Imaging Assessment
Large Vessel Vasculitis
For Giant Cell Arteritis:
- Ultrasound is now first-line imaging - examine temporal, axillary, and extracranial carotid arteries for halo sign (vessel wall edema) 10
- Alternative modalities: FDG-PET or MRI of cranial and extracranial arteries if ultrasound unavailable 10
- Consider whole-body imaging (CTA chest/abdomen/pelvis or FDG-PET/CT) to detect large-vessel GCA, which presents differently and requires different management than cranial GCA 9
For Takayasu Arteritis:
- MRI/MRA is preferred - assess vessel wall thickening, edema, and enhancement 10
- Alternatives: FDG-PET/CT, CTA, or ultrasound 10
- Coverage should include aorta and major branches 9
Medium-Small Vessel Vasculitis
Imaging plays a limited role in diagnosis but may show:
- Chest CT: pulmonary nodules, infiltrates, or hemorrhage
- Angiography: microaneurysms in polyarteritis nodosa
- Cardiac imaging: for EGPA with suspected cardiac involvement 6
Clinical Assessment Framework
Categorize Disease Severity
Organ-threatening/life-threatening manifestations requiring aggressive therapy 1:
- Glomerulonephritis (especially rapidly progressive)
- Pulmonary hemorrhage
- Central nervous system involvement
- Cardiac involvement
- Mesenteric vasculitis
- Mononeuritis multiplex
- Retro-orbital disease
Non-organ-threatening manifestations 1:
- Nasal/sinus disease without bony erosion
- Skin involvement without ulceration
- Non-cavitating pulmonary nodules
- Episcleritis
- Myositis (skeletal muscle only)
Exclude Infection Before Immunosuppression
This is critical and non-negotiable. Screen for:
- Active bacterial infections (blood cultures, imaging as indicated)
- Tuberculosis (especially before rituximab or cyclophosphamide)
- Hepatitis B and C
- HIV
- Other endemic infections based on geography 4
Special Considerations and Pitfalls
Common diagnostic errors:
- Waiting for biopsy in rapidly progressive disease when ANCA-positive - start treatment immediately 4, 8
- Using immunofluorescence alone for ANCA testing instead of antigen-specific assays 1
- Missing large-vessel GCA by only examining temporal arteries 9
- Attributing elevated inflammatory markers solely to infection when vasculitis is present 11
ANCA-negative vasculitis: Up to 25% of small vessel vasculitis may be ANCA-negative. In this setting, biopsy becomes even more critical for diagnosis 3, 1. Consider alternative diagnoses more carefully.
EGPA-specific: ANCA-positive patients (typically MPO-ANCA) have more "vasculitic" phenotype with glomerulonephritis and neuropathy, while ANCA-negative patients have worse prognosis due to higher frequency of cardiomyopathy 6
Management at Expert Centers
All patients with suspected or confirmed vasculitis should be managed at, or in close collaboration with, centers of expertise 3, 7, 5, 1. These rare, heterogeneous, potentially life-threatening diseases require:
- Multidisciplinary teams
- Access to specialized imaging
- Experience with immunosuppressive protocols
- Long-term monitoring capabilities
- Enrollment in clinical trials for refractory cases